Toronto, Ontario – The Newswire – September 08, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce its participation as a Gold Sponsor for the highly anticipated 8th Annual Paediatric Echo Society Symposium. The event will take place in Orlando, Florida on September 9th, 2023.
The Paediatric Echo Society Symposium, a nation-wide event, is staged by Advent Health for cardiologists and sonographers. The symposium aims to foster collaboration, share cutting-edge research, and discuss best practices in paediatric echocardiology. The symposium will feature an array of educational sessions, panel discussions, and demonstrations.
Ventripoint will have a prominent presence throughout the symposium, showcasing the latest diagnostic advancements of the VMS+ and hosting an interactive booth, offering attendees the opportunity to engage with the team and experience the VMS+.
“We are thrilled to be a sponsor for the 8th Annual Paediatric Echo Society Symposium,” said Dr. Alvira Macanovic, President and CEO of Ventripoint Diagnostics. “This event promises to be a great platform to exchange knowledge and experiences among experts in the field of paediatric cardiology.”
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Jonathan Robinson
This email address is being protected from spambots. You need JavaScript enabled to view it.
416-669-1001
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Last Trade: | C$0.14 |
Daily Volume: | 54,133 |
Market Cap: | C$22.330M |
November 14, 2024 November 06, 2024 October 24, 2024 October 11, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB